 |
Vol.55 No.6 contents | Japanese/English |
 | Full Text of PDF (294K) Article in Japanese |
- Review Article -
Targeting RET Fusion Genes -Translation to Personalized Lung Cancer Therapy-
Makoto Nishio11Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
The identification of driver mutations and the development of targeted therapies have significantly changed the treatment of non-small cell lung cancer (NSCLC). The rearranged during transfection (RET) fusion gene was first identified in 1985. Somatic RET mutations have been observed in 30-50% of sporadic medullary thyroid cancer, and somatic RET gene fusions have been observed in 30-50% of sporadic papillary thyroid cancer. In 2012, four studies identified fusions of the RET oncogene in NSCLC and RET fusion genes were present in 1-2% of lung adenocarcinomas. In addition, sorafenib, sunitinib, cabozantinib, vandetanib, ponatinib, lenvatinib, and regorafenib (BAY 73-4506) are known as multi-target agents which have significant activity against RET, and some of these agents have been approved for the treatment of advanced medullary thyroid cancer or other cancers. Therefore, these agents will be available as RET inhibitors for NSCLC with RET fusion genes in the clinical setting, and several clinical studies are currently ongoing. In this symposium, the current situation of the development of RET inhibitors will be reviewed.
key words: Driver mutation, Fusion gene, RET, Non-small cell lung cancer (NSCLC), Tyrosine kinase inhibitor
JJLC 55 (6): 885-888, 2015
